Epstein-Barr Virus-Positive Diffuse Large B-cell Lymphoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Epstein–Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) of both younger and elderly population and was defined as EBV-positive monoclonal large B-cell proliferative disease. The survival of patients with EBV-positive DLBCL is significantly worse than that of patients with EBV-negative DLBCL. Cells with latent EBV infection express EBER protein and may express other proteins such as EBNA and LMP proteins. EBV also induces the NFκB pathway, which may be required for the survival of the cells in DLBCL. The immunohistochemical profile is generally positive for B-cell markers CD20, CD19, CD79a, and PAX-5. CD10 and BCL6 are usually negative, while MUM1 is commonly positive. Cases with immunoblastic or plasmablastic features may lack CD20 expression. In situ hybridization for EBER is positive and is considered the most important test in diagnosis, with the highest diagnostic sensitivity. EBV+ DLBCL has a poor response to treatment, so rapid detection is a necessity.
·
The prevalence of EBV positive DLBCL was 14.0%
and 10.4% for EBER cut-off of 20% and 50%, respectively
·
The EBV positive DLBCL of the elderly accounts
for 8.7%–11.4% of all DLBCL in Asian countries, less than 5% in western
nations. Since the introduction of rituximab, R-CHOP has become the standard
treatment for CD20 positive DLBCL.
Thelansis’s
“Epstein-Barr Virus-Positive Diffuse Large B-cell Lymphoma Market Outlook,
Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033"
covers disease overview, epidemiology, drug utilization, prescription share
analysis, competitive landscape, clinical practice, regulatory landscape,
patient share, market uptake, market forecast, and key market insights under
the potential Epstein-Barr Virus-Positive Diffuse Large B-cell Lymphoma
treatment modalities options for eight major markets (USA, Germany, France,
Italy, Spain, UK, Japan, and China).
KOLs insights of Epstein-Barr
Virus-Positive Diffuse Large B-cell Lymphoma across 8 MM market from the centre
of Excellence/ Public/ Private hospitals participated in the study. Insights
around current treatment landscape, epidemiology, clinical characteristics,
future treatment paradigm, and Unmet needs.
Epstein-Barr
Virus-Positive Diffuse Large B-cell Lymphoma Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Tags: Epstein-Barr
Virus-Positive Diffuse Large B-cell Lymphoma, Epstein-Barr Virus-Positive
Diffuse Large B-cell Lymphoma market outlook, Epstein-Barr
Virus-Positive Diffuse Large B-cell Lymphoma competitive
landscape, Epstein-Barr Virus-Positive Diffuse Large B-cell Lymphoma market forecast, Thelansis, Primary market research, KOL
insights, Competitive Intelligence (CI)
Comments
Post a Comment